Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
Commentary|Articles|October 6, 2026
MFN Raises the Stakes for Japan Launch Pricing
Author(s)Na Wei
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Advertisement
Advertisement
Japan launch pricing has become more consequential against the backdrop of the U.S. most-favored-nation (MFN) policy. Japan is included in the reference basket contemplated under several MFN models, meaning a low launch price can affect pricing well beyond the domestic market.
Related to this article
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Advertisement
Advertisement